PEP-Therapy extends Series-A financing, raising a total of €5.4 million to progress the clinical development of its lead candidate PEP-010

as well as a €1 million loan from Bpifrance
PARIS, July 19, 2021 /PRNewswire/ -- 
PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies for the treatment of cancers, announced today that it raised an additional €2.6 million ($3 million) in an extension of its Series A financing round, bringing the total raised in this round to €5.4 million ($6.4 million). This new funding comprises €1.6 million in equity from Anaxago, i&i Prague and BADGE as well as a €1 million loan from Bpifrance.
This increased financial support highlights the potential of PEP-010, as well as PEP-Therapy's Cell Penetrating & Interfering Peptide (CP&IP) technology platform, which was first developed at Sorbonne University and Institut Curie.

Related Keywords

Italy ,Czech Republic ,Prague ,Praha ,Hlavníesto ,Paris ,France General ,France ,French ,Italian ,Laboratoires Fournier ,Bernard Majoie ,Antoine Prestat ,Gustave Roussy ,Sylvie Berrebi ,Institut Curie ,Gaston Vasseur ,Seed Fund ,Sorbonne University ,Fournier Majoie Foundation For Innovation ,Bpifrance This ,Cell Penetrating ,Interfering Peptide ,Investment Manager ,Fonds Unique Interminist ,Interfering Peptides ,Italian Angels ,Magna Capital Partners ,Business Angels Des Grandes Ecoles ,Seventure Partners ,Founding Chairman ,Fournier Majoie Foundation ,Anaxago Venture Capital ,Venture Capital ,Angels Des Grandes Ecoles ,French Business Angels ,இத்தாலி ,செக் குடியரசு ,ப்ராக் ,பிரதா ,பாரிஸ் ,பிரான்ஸ் ,பிரஞ்சு ,இத்தாலிய ,நிறுவனம் கியூரி ,விதை நிதி ,சோர்போன் பல்கலைக்கழகம் ,செல் ஊடுருவி ,முதலீடு மேலாளர் ,இத்தாலிய தேவதூதர்கள் ,மாக்னா மூலதனம் கூட்டாளர்கள் ,ஸ்தாபகம் தலைவர் ,துணிகர மூலதனம் ,